|
Recent
developments in the treatment of gastrointestinal
disorders
PARIET™ (rabeprazole)
PARIET (rabeprazole sodium) is a new
treatment for gastro-oesophageal reflux
disease (GORD), duodenal and gastric
ulcers. It works by suppressing acid,
resulting in less acidic exposure
to the lining of the stomach. Janssen-Cilag
is marketing PARIET™ in a number
of countries together with Eisai,
which synthesized and developed the
medicine.
Foundations
for future growth
Future developments are numerous
and varied. After the discovery of
the antidiarrhoeal drug loperamide,
Janssen's researchers succeeded in
further refining the loperamide molecule
to obtain a compound with even greater
selectivity: loperamide oxide. Activated
only when it reaches the intestinal
cells, this drug may play a role in
the treatment of diarrhoea in the
future.
Chronic constipation has a significant
impact on quality of life. While changes
in diet and life-style sometimes alleviate
the condition, in a substantial number
of cases drug therapy is needed. Laxatives
are frequently used, but are sometimes
not appropriate for chronic treatment
and do not relieve all symptoms involved.
Research has shown that stimulation
of 5-HT4 receptors along the gastro-intestinal
tract enhances the motility of both
the small and large intestine.
Do you want to know more about
this subject?
Please explore www.diarree.be,
our intersite which offers you all
possbile answers on questions related
to diarrhoea and its treatment.
|
